ScholarIQanswers from OpenAlex
Diabetes Obesity and Metabolism
JournalCitation impact & published research
Diabetes Obesity and Metabolism is a journal indexed in ScholarIQ from OpenAlex.
How many works does Diabetes Obesity and Metabolism have?
ScholarIQindexed works
Diabetes Obesity and Metabolism has 7,929 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Diabetes Obesity and Metabolism have?
ScholarIQcitation count
Diabetes Obesity and Metabolism has 240,631 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Diabetes Obesity and Metabolism?
ScholarIQh-index
Diabetes Obesity and Metabolism has an h-index of 186 in OpenAlex.
What is the article processing charge of Diabetes Obesity and Metabolism?
ScholarIQarticle processing charge
Diabetes Obesity and Metabolism lists an article processing charge of 4,940 USD in OpenAlex.
What is the OpenAlex record for Diabetes Obesity and Metabolism?
ScholarIQopenalex
The OpenAlex for Diabetes Obesity and Metabolism is on the source record.
What are the most-cited papers on Diabetes Obesity and Metabolism?
ScholarIQmost cited works
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension
John Wilding, Rachel L. Batterham, Melanie J. Davies, Luc F. Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, Barbara McGowan, Tuğçe Kalaycı Oral, Julio Rosenstock, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Robert F. Kushner, STEP 1 Study Group
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Robert Ćhilton, I. Tikkanen, Christopher P. Cannon, S. Crowe, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
Francesco Zaccardi, David R. Webb, Zin Zin Htike, Dina Ahmed Hosney Youssef, Kamlesh Khunti, Melanie J. Davies
Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis
Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley, John J.V. McMurray, David W. Boulton
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
Jan Bolinder, Östen Ljunggren, Lars Johansson, John Wilding, AM Langkilde, C. David Sjöström, Jennifer Sugg, Shamik Parikh